Advertisement

GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER’S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE

  • Ellen Dicks
    Affiliations
    Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
    Search for articles by this author
  • Wiesje M. van der Flier
    Affiliations
    Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

    Department of Epidemiology and Biostatistics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
    Search for articles by this author
  • Frederik Barkhof
    Affiliations
    Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

    Institutes of Neurology and Healthcare Engineering, UCL, London, United Kingdom
    Search for articles by this author
  • Philip Scheltens
    Affiliations
    Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
    Search for articles by this author
  • Betty M. Tijms
    Affiliations
    Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
    Search for articles by this author
      For the development of therapies measures are needed to monitor disease progression in Alzheimer’s disease (AD). Grey matter connectivity is disrupted in AD, manifesting already in preclinical stages due to aggregating amyloid, and is related to disease progression in predementia AD. It remains unclear, how these disruptions evolve over time and whether they translate to cognitive decline within individuals across the disease continuum.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'